$0.75
2.55% today
Nasdaq, Feb 05, 03:48 pm CET
ISIN
US2666051048
Symbol
DRRX
Sector
Industry

DURECT Corporation Stock price

$0.77
-0.10 11.06% 1M
-0.59 43.40% 6M
+0.02 2.63% YTD
-0.01 1.62% 1Y
-6.26 89.05% 3Y
-16.43 95.53% 5Y
-9.63 92.60% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.02 2.60%
ISIN
US2666051048
Symbol
DRRX
Sector
Industry

Key metrics

Market capitalization $23.89m
Enterprise Value $27.25m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.17
P/S ratio (TTM) P/S ratio 2.78
P/B ratio (TTM) P/B ratio 19.63
Revenue growth (TTM) Revenue growth -6.53%
Revenue (TTM) Revenue $8.59m
EBIT (operating result TTM) EBIT $-19.34m
Free Cash Flow (TTM) Free Cash Flow $-21.90m
Cash position $10.38m
EPS (TTM) EPS $-0.67
P/E forward negative
P/S forward 1.85
EV/Sales forward 2.11
Short interest 3.18%
Show more

Is DURECT Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

DURECT Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a DURECT Corporation forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a DURECT Corporation forecast:

Buy
67%
Hold
33%

Financial data from DURECT Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
8.59 8.59
7% 7%
100%
- Direct Costs 1.82 1.82
16% 16%
21%
6.85 6.85
10% 10%
80%
- Selling and Administrative Expenses 12 12
24% 24%
139%
- Research and Development Expense 14 14
58% 58%
165%
-19 -19
54% 54%
-226%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -19 -19
54% 54%
-225%
Net Profit -17 -17
53% 53%
-199%

In millions USD.

Don't miss a Thing! We will send you all news about DURECT Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

DURECT Corporation Stock News

Neutral
PRNewsWire
one day ago
CUPERTINO, Calif. , Feb. 4, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E.
Neutral
PRNewsWire
8 days ago
The article presents new trial data, including subgroup analyses and liver biomarkers, which have guided the design of the Company's planned Phase 3 trial CUPERTINO, Calif. , Jan. 28, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the publication of a peer-reviewed article on the AHFIRM trial data in NEJM Evidence.
Neutral
PRNewsWire
2 months ago
CUPERTINO, Calif. , Nov. 25, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announced the sale of its ALZET® line of osmotic pumps to Lafayette Instrument Co. (LIC), a portfolio company of Branf...
More DURECT Corporation News

Company Profile

DURECT Corp. is a biopharmaceutical company. It engages in the research, development, and manufacturing of pharmaceutical products. The company products include alzet and lactel. Its pipeline includes DUR-928, which focuses on lipid homeostasis, inflammation, and cell survival; and POSIMIR, which is an analgesic product intended to deliver bupivacaine to provide pain relief after surgery. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.

Head office United States
CEO James Brown
Employees 58
Founded 1998
Website www.durect.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today